Host factors and failure of interferon-α treatment in hepatitis C virus

Authors

  • Bin Gao,

    Corresponding author
    1. Section on Liver Biology, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD
    • Section on Liver Biology, NIAAA/NIH, Park Bldg., Rm. 120, 12420 Parklawn Drive, MSC 8115, Bethesda, MD 20892
    Search for more papers by this author
  • Feng Hong,

    1. Section on Liver Biology, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Svetlana Radaeva

    1. Section on Liver Biology, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD
    Search for more papers by this author

Abstract

Failure of interferon-α (IFN-α) treatment in patients with chronic hepatitis C virus (HCV) infection is a challenging obstacle for clinical and experimental hepatology. Both viral and host factors have been implicated in reducing responsiveness to IFN-α therapy. The role of viral factors has been studied extensively and has been summarized in several review articles; however, much less attention has been paid to host factors. In this paper, we review evidence of host factor involvement in IFN-α treatment failure. We discuss possible underlying mechanisms responsible for these effects. Potential therapeutic strategies to enhance the effectiveness of IFN-α therapy for HCV are also proposed. (HEPATOLOGY 2004;39:880ndash;890.)

Ancillary